SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-18-158327
Filing Date
2018-05-10
Accepted
2018-05-10 07:07:18
Documents
41
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d564302d10q.htm 10-Q 213535
2 EX-31.1 d564302dex311.htm EX-31.1 6003
3 EX-32.1 d564302dex321.htm EX-32.1 3196
  Complete submission text file 0001193125-18-158327.txt   1518181

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT rxii-20180331.xml EX-101.INS 207484
5 XBRL TAXONOMY EXTENSION SCHEMA rxii-20180331.xsd EX-101.SCH 20318
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rxii-20180331_cal.xml EX-101.CAL 30555
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rxii-20180331_def.xml EX-101.DEF 51685
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE rxii-20180331_lab.xml EX-101.LAB 188781
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rxii-20180331_pre.xml EX-101.PRE 126248
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 18820461
SIC: 2834 Pharmaceutical Preparations